ArticleArchives of orthopaedic and trauma surgery2026
Chronic infections of knee megaprostheses: are "Off-Label" DAIR-Plus or partial two-stage exchange viable options?
Article in Archives of orthopaedic and trauma surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTwo-stage revision for chronic periprosthetic joint infections (PJI) of knee megaprostheses is complex and often results in significant bone loss. DAIR-Plus and other partial exchange procedures, involving debridement with partial prosthesis removal but retaining stems, are typically used for acute PJI but may benefit select chronic cases. This study aimed to: (i) assess DAIR-Plus and partial two-stage exchange outcomes in chronic megaprosthesis infections; and (ii) identify prognostic factors to guide their use versus full component removal. MATERIALS AND
methodsTwenty-three patients underwent DAIR-Plus or partial two-stage exchange (PTSE) procedures for chronic knee megaprosthetic PJI between 2000 and 2022. Nineteen patients, were included. Targeted antibiotics were administered based on Infectious Disease Specialist recommendations. Infection eradication was evaluated using clinical and serologic parameters.
resultsNineteen patients (mean age 53.4 years) underwent 13 DAIR-Plus and 7 PTSE. PJI-free survival was 57.9% at 1 year, 47.4% at 2 and 5 years, and 42% beyond 5 years. Among failures, 6 had persistent infection and 5 relapsed (mean time to relapse: 13.75 months). Four additional patients achieved infection control after further two-stage revisions; 7 remained uncontrolled, leading to 6 amputations and 1 chronic suppressive treatment. Outcomes did not differ significantly by age, gender, host status, oncological history, radiotherapy, or surgical approach. Staphylococcus spp. caused 63% of infections and were associated with significantly lower PJI-free survival at final follow-up (25% vs. 62% for other organisms, p = 0.048).
conclusionsDAIR-Plus provided lasting infection control in selected chronic PJI cases, with nearly half remaining infection-free long term with notable advantages such as bone stock preservation and faster recovery. Partial two-stage exchange does not appear to offer additional advantages over DAIR-Plus. Outcomes were not influenced by clinical factors, but Staphylococcus spp. infections showed significantly lower success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.